Literature DB >> 10626537

Overview of the effects of cancer therapies: the nature, scale and breadth of the problem.

C A Sklar1.   

Abstract

Over the past 30 years, the striking improvements in the survival rates of patients with childhood cancers are due, in large part, to the use of aggressive treatment strategies. These therapeutic modalities are associated with a variety of late complications that span a spectrum from minor and treatable to serious and occasionally lethal. Nearly one-quarter of the late deaths in survivors of childhood cancer can be attributed to a treatment-related effect, for example, a subsequent malignant neoplasm or cardiac dysfunction. The risk of late death due to causes other than recurrence is greatest in survivors treated with the combination of chemotherapy and radiotherapy. Among the 650 survivors followed in the Long-Term Follow-Up Clinic at the Memorial Sloan-Kettering Cancer Center, the most common sequelae are endocrine complications, which are seen in 40% of the patients. Growth hormone deficiency, primary hypothyroidism and primary ovarian failure are the endocrine disorders observed most often.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10626537     DOI: 10.1111/j.1651-2227.1999.tb14395.x

Source DB:  PubMed          Journal:  Acta Paediatr Suppl        ISSN: 0803-5326


  15 in total

Review 1.  Endocrine sequelae of cancer therapy in childhood.

Authors:  F B Diamond; B B Bercu
Journal:  J Endocrinol Invest       Date:  2001-10       Impact factor: 4.256

2.  Health care of young adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.

Authors:  Kevin C Oeffinger; Ann C Mertens; Melissa M Hudson; James G Gurney; Jacqueline Casillas; Hegang Chen; John Whitton; Mark Yeazel; Yutaka Yasui; Leslie L Robison
Journal:  Ann Fam Med       Date:  2004 Jan-Feb       Impact factor: 5.166

Review 3.  Pediatric brain tumor treatment: growth consequences and their management.

Authors:  Sogol Mostoufi-Moab; Adda Grimberg
Journal:  Pediatr Endocrinol Rev       Date:  2010-09

Review 4.  Long-term effects of radiation exposure among adult survivors of childhood cancer: results from the childhood cancer survivor study.

Authors:  Gregory T Armstrong; Marilyn Stovall; Leslie L Robison
Journal:  Radiat Res       Date:  2010-09-17       Impact factor: 2.841

5.  Combined central precocious puberty and primary gonadal failure after treatment of childhood malignancy in two boys: a diagnostic and therapeutic conundrum.

Authors:  Zeina M Nabhan; Jakub Mieszczak; Erica A Eugster
Journal:  J Pediatr       Date:  2010-06-12       Impact factor: 4.406

6.  Nutritional intake of long-term survivors of childhood acute lymphoblastic leukemia: evidence for bone health interventional opportunities.

Authors:  Frances A Tylavsky; Karen Smith; Harriet Surprise; Sarah Garland; Xiaowei Yan; Elizabeth McCammon; Melissa M Hudson; Ching-Hon Pui; Sue C Kaste
Journal:  Pediatr Blood Cancer       Date:  2010-12-15       Impact factor: 3.167

7.  Attendance at a survivorship clinic: impact on knowledge and psychosocial adjustment.

Authors:  Jennifer S Ford; Joanne F Chou; Charles A Sklar
Journal:  J Cancer Surviv       Date:  2013-06-22       Impact factor: 4.442

8.  Quality of life in long-term childhood cancer survivors and the relation of late effects and subjective well-being.

Authors:  Sigrid Pemberger; Reinhold Jagsch; Eva Frey; Rosemarie Felder-Puig; Helmut Gadner; Ilse Kryspin-Exner; Reinhard Topf
Journal:  Support Care Cancer       Date:  2004-11-23       Impact factor: 3.603

9.  Differences in activities of daily living performance between long-term pediatric sarcoma survivors and a matched comparison group on standardized testing.

Authors:  Rebecca Parks; Elizabeth K Rasch; Patrick J Mansky; Frances Oakley
Journal:  Pediatr Blood Cancer       Date:  2009-10       Impact factor: 3.167

10.  Endocrine sequelae of cancer and cancer treatments.

Authors:  Charles J Stava; Camilo Jimenez; Rena Vassilopoulou-Sellin
Journal:  J Cancer Surviv       Date:  2007-11-20       Impact factor: 4.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.